Location History:
- Salt Lake City, UT (US) (2000 - 2003)
- Allston, MA (US) (2001 - 2005)
- Alston, MA (US) (2002 - 2007)
- Boston, MA (US) (2007)
- Dorchester, MA (US) (2007)
Company Filing History:
11 out of 1,645 
1 out of 3 
1 out of 1,327 
Years Active: 2000-2007
Title: **Igor Splawski: Innovator in Genetic Research**
Introduction
Igor Splawski, based in Alston, Massachusetts, is a notable inventor with a strong focus on genetic research, particularly in relation to long QT syndrome. With a total of 16 patents to his name, his contributions have significantly advanced the understanding of gene mutations and their implications for cardiac health.
Latest Patents
Igor's latest patents revolve around the genomic structure of the HERG gene, which is closely associated with long QT syndrome. His inventions detail the determination of the sequences of the 15 intron/exon junctions of this gene, providing valuable information for developing primers that can amplify and sequence all exons. This innovation plays a crucial role in identifying the presence of mutations that contribute to long QT syndrome.
Additionally, Igor's patents disclose the genomic structure of the KCNE1 gene, which encodes human minK and is implicated in arrhythmia susceptibility. The detailed sequence data enhances the ability to screen individuals for genetic mutations leading to long QT syndrome. These patents also allow for the development of assays that can be utilized to detect mutations in both DNA and proteins, facilitating drug screening that may help in treating or preventing long QT syndrome.
Career Highlights
Throughout his career, Igor has made significant strides in genetic research, contributing to advancements in our understanding of cardiovascular genetics. He has been associated with esteemed organizations, including the University of Utah Research Foundation, where he has collaborated on groundbreaking projects.
Collaborations
Igor has worked alongside esteemed colleagues such as Mark T. Keating and Michael C. Sanguinetti, both of whom have also made significant contributions to the field of genetics and heart health. Their combined efforts underscore the importance of collaboration in driving innovation and improving patient outcomes in genetic disorders.
Conclusion
Igor Splawski's dedication to the field of genetic research has led to substantial advancements in understanding and addressing long QT syndrome. His numerous patents and collaborative work highlight the critical role that innovation plays in the development of medical solutions for complex genetic conditions. As research continues to evolve, the impact of Igor's contributions will undoubtedly be felt in the medical community and beyond.